dpp-4 inhibitors and glp-1 agonists Mechanism of action for GIP, analogues DPP4 in The DPP-4 inhibitor linagliptin and

Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus

Overall, randomized controlled clinical trials showed that high persistence regarding GLP-1 RA treatment could be maintained for periods up to 5 years, which contrasts with data from observational studies (as previously described)

The biggest risk reduction was for non-small cell lung cancer (50%), followed by breast cancer (43%), colorectal cancer (31%) and liver cancer (38%)

Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Your Patients With Obesity, Without T2D high risk for cardiovascular disease

There is no single best procedure for everyone